There were 173 press releases posted in the last 24 hours and 437,701 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Kadmon Corporation Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Non-Small Cell Lung Cancer With Activating EGFR Mutations and Brain Metastases or Leptomeningeal Disease

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image